NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / Gilead Sciences
Originally published by SAN FRANCISCO BUSINESS TIMES on bizjournals.com
Much has changed since Daniel O’Day, chairman and CEO, arrived at Gilead Sciences in 2019. The company has grown considerably and expanded on its long-standing leadership in antiviral therapies to include a focus on cancer medicines. Today the Foster City-based company is the second-largest biotech employer in the Bay Area, and according to a Bay Area Council report, it created an estimated economic impact of $22.1 billion in 2020 alone. It has more than 25 marketed therapies for HIV, cancer, hepatitis, COVID-19 and other diseases, and one of the strongest and most diverse pipelines of new medicines in its history.
Continue reading here
View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.
Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com
SOURCE: Gilead Sciences
View the original press release on accesswire.com
TORONTO, ON / ACCESSWIRE / April 5, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero"…
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…
LAS VEGAS, NV / ACCESSWIRE / April 5, 2024 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNH)…
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilitiesTORONTO, April 05, 2024 (GLOBE NEWSWIRE)…
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway…